205 related articles for article (PubMed ID: 9674734)
1. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Bendz B; Ostergaard P; Nordøy A
Br J Haematol; 1998 Jun; 101(4):638-46. PubMed ID: 9674734
[TBL] [Abstract][Full Text] [Related]
2. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.
Bendz B; Hansen JB; Andersen TO; Ostergaard P; Sandset PM
Br J Haematol; 1999 Dec; 107(4):756-62. PubMed ID: 10606880
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
Hansen JB; Sandset PM
Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
[TBL] [Abstract][Full Text] [Related]
4. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study.
Naumnik B; Borawski J; Myśliwiec M
Nephrol Dial Transplant; 2003 Jul; 18(7):1376-82. PubMed ID: 12808176
[TBL] [Abstract][Full Text] [Related]
5. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
Altman R; Scazziota A; Rouvier J
Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
[TBL] [Abstract][Full Text] [Related]
7. Intravascular release and urinary excretion of tissue factor pathway inhibitor during heparin treatment.
Brodin E; Svensson B; Paulssen RH; Nordoy A; Hansen JB
J Lab Clin Med; 2004 Nov; 144(5):246-53; discussion 226-7. PubMed ID: 15570242
[TBL] [Abstract][Full Text] [Related]
8. The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Hoppensteadt DA; Jeske W; Fareed J; Bermes EW
Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S57-64. PubMed ID: 7647223
[TBL] [Abstract][Full Text] [Related]
9. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Hoppensteadt DA; Walenga JM; Fasanella A; Jeske W; Fareed J
Thromb Res; 1995 Jan; 77(2):175-85. PubMed ID: 7740509
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor pathway inhibitor release induced by defibrotide and heparins.
Cella G; Sbarai A; Mazzaro G; Motta G; Carraro P; Andreozzi GM; Hoppensteadt DA; Fareed J
Clin Appl Thromb Hemost; 2001 Jul; 7(3):225-8. PubMed ID: 11441984
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
Alban S; Gastpar R
Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a low molecular weight heparin administered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. Certoparin-Study Group.
Kirchmaier CM; Wolf H; Schäfer H; Ehlers B; Breddin HK
Int Angiol; 1998 Sep; 17(3):135-45. PubMed ID: 9821025
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
Li Y; Rodriquez M; Spencer FA; Becker RC
J Thromb Thrombolysis; 2002 Oct; 14(2):123-9. PubMed ID: 12714831
[TBL] [Abstract][Full Text] [Related]
14. The effect of unfractionated vs. low molecular weight heparin on tissue factor pathway inhibitor levels in hospital inpatients.
Brown JR; Kuter DJ
Thromb Haemost; 2001 Jun; 85(6):979-85. PubMed ID: 11434705
[TBL] [Abstract][Full Text] [Related]
15. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
[TBL] [Abstract][Full Text] [Related]
16. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin.
Mousa SA; Linhardt R; Francis JL; Amirkhosravi A
Thromb Haemost; 2006 Dec; 96(6):816-21. PubMed ID: 17139378
[TBL] [Abstract][Full Text] [Related]
17. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
Vila V; Martínez-Sales V; Réganon E; Peris E; Perez F; Ruano M; Aznar J
Haematologica; 2001 Jul; 86(7):729-34. PubMed ID: 11454528
[TBL] [Abstract][Full Text] [Related]
18. Heparin blunts endotoxin-induced coagulation activation.
Pernerstorfer T; Hollenstein U; Hansen J; Knechtelsdorfer M; Stohlawetz P; Graninger W; Eichler HG; Speiser W; Jilma B
Circulation; 1999 Dec 21-28; 100(25):2485-90. PubMed ID: 10604885
[TBL] [Abstract][Full Text] [Related]
19. Physiological function of tissue factor pathway inhibitor and interaction with heparins.
Sandset PM; Bendz B; Hansen JB
Haemostasis; 2000; 30 Suppl 2():48-56. PubMed ID: 11251341
[TBL] [Abstract][Full Text] [Related]
20. Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture.
Lupu C; Poulsen E; Roquefeuil S; Westmuckett AD; Kakkar VV; Lupu F
Arterioscler Thromb Vasc Biol; 1999 Sep; 19(9):2251-62. PubMed ID: 10479670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]